Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

RICHMOND, Va., March 10, 2011 /PRNewswire/ -- Insmed Inc. (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2010.

Key Recent Highlights:

  • Filed Investigational New Drug (IND) Application in February 2011 with the FDA to begin a phase 3 clinical trial for ARIKACE™ (liposomal amikacin for inhalation) in non-TB Mycobacteria (NTM) lung infections.
  • Successfully concluded 72 week phase 2b open-label study for ARIKACE for pseudomonas lung infections in cystic fibrosis (CF) patients.
  • Received positive opinion from European Medicines Agency (EMA) on Company's Pediatric Investigation Plan for ARIKACE in the CF indication.
  • Gained shareholder approval for conversion of preferred stock into common stock and 1:10 reverse stock split.

  • "Following the closure of our transformative business combination in December 2010, we have been aggressively moving forward with the development plan for ARIKACE, our phase 3 compound for pseudomonas lung infections for CF patients, and NTM lung infections," said Timothy Whitten, Insmed's President & CEO.  "We are well underway with the initial preparations and necessary work around these trials and continue to expect to begin accruing patients to the phase 3 trials in both indications in the second half of 2011, with results expected in the first half of 2013."

    Financial ResultsOn March 1, 2011, at a special meeting, our shareholders approved a one for 10 reverse stock split of our common stock, which became effective at 5:00 pm EST on March 2, 2011.  This reverse stock split is reflected in the shares outstanding and earnings per share calculations below.  

    Revenues for the fourth quarter ended December 31, 2010 were $1.3 million, as compared to $2.5 million for the corresponding period in 2009.  The $1.2 million decrease resulted from $0.6 million in lower cost r
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Insmed to Host Second Quarter 2009 Conference Call
    2. Insmed Announces Addition to the Russell 3000(R) Index
    3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
    4. Insmed CEO Resigns Due to Health Concerns
    5. Insmed Announces First Quarter 2009 Financial Results
    6. Insmed Regains NASDAQ Compliance
    7. Insmed to Host First Quarter 2009 Conference Call
    8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
    9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
    10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
    11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
    (Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
    (Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest ... the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge ... of US$15,000 and a period of expert mentorship from a senior industry figure drawn ...
    (Date:7/1/2015)... STRATFORD, CONNECTICUT (PRWEB) , ... July 01, 2015 ... ... disinfected or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have ... of medical devices now have an operator control device that will increase healthcare ...
    Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
    ... ... Biodiesel Refinery, HOUSTON, March 4 ... has satisfied the conditions precedent,and completed its first funding of $10.6 ... one of the world,s leading,financial services providers for alternative energy companies. ...
    ... Forget About Storage and Focus on Business, NEW ... provider, announces the launch of ExaStore Clustered NAS 2008,designed ... full range of,applications and environments., "Organizations have seen ... considerable burden," says Dr. Arnon Gat, Exanet,President & CEO. ...
    ... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
    Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Exanet Announces ExaStore 2008 Clustered NAS System 2Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2
    (Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
    (Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
    (Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
    Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
    ... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ...
    ... ages will celebrate the science and technology of the ... the inaugural Atlanta Science Festival, March 22-29, 2014. With ... schools and universities, the festival will host more than ... across the city. Learn more at http://atlantasciencefestival.org . ...
    ... Cargo in Efficient and Sustainable Global Logistics Operations) is ... in the efficiency of intermodal loading systems and the ... comprises 29 European organisations with experience in the logistics ... budget totalling 17,000,000 and a duration of three and ...
    Cached Biology News:New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2
    ... versatile Zymo-Spin I-96 Plate can be used ... for the large-scale (i.e., 96-well) purification of ... construction and unique silica-based matrix make it ... DNA or RNA in = 10 l ...
    ...
    ...
    ...
    Biology Products: